← Leaderboards
Yi Zheng
University Of Tennessee Health Sci Ctr
$32,153,231
Attributed
$41,111,841
Total exposure
30
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,372,476 · 31
By mechanism
R01$29,923,288 · 16
U54$5,291,356 · 3
P30$3,953,086 · 1
R44$2,046,979 · 1
R43$1,843,946 · 5
T32$835,321 · 1
Top collaborators
- Hartmut Geiger15 shared
- James C Mulloy11 shared
- Jose A. Cancelas7 shared
- Fukun Guo7 shared
- Daniel Starczynowski5 shared
- Brittany De Kouchkovsky2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsSignal TransductionMolecularIn VivoBaseGeneticMouse ModelRho Gtp-Binding ProteinsStem CellsHematopoietic Stem CellsIn VitroAffectFutureInhibitor/AntagonistMediatingFamilyHematopoieticStructureMemberMalignant NeoplasmsTransplantationGuanosine Triphosphate PhosphohydrolasesBloodPhenotype
Grant awards (126)
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2025 · DK · contact PI
Rational targeting of Cdc42 to benefit immunotherapy$594,402
R01 · FY2025 · CA · contact PI
Administrative Core$206,140
U54 · FY2025 · DK · contact PI
Rho GTPase inhibitor for refrigerated platelet storage$1,188,244
R44 · FY2024 · HL
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2024 · DK · contact PI
Rational targeting of Cdc42 to benefit immunotherapy$594,402
R01 · FY2024 · CA · contact PI
Novel mechanism of intestinal stem cell aging$505,734
R01 · FY2024 · AG · contact PI
Pharmacological rejuvenation of human hematopoietic stem cells$299,781
R43 · FY2024 · HL
Administrative Core$206,140
U54 · FY2024 · DK · contact PI
Rho GTPase inhibitor for refrigerated platelet storage$858,735
R44 · FY2023 · HL
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2023 · DK · contact PI
Novel mechanism of intestinal stem cell aging$505,734
R01 · FY2023 · AG · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$437,206
R01 · FY2023 · CA
Administrative Core$206,140
U54 · FY2023 · DK · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2022 · DK · contact PI
Small molecules targeting RhoA for platelet cold storage in cancer care$635,494
R01 · FY2022 · HL · contact PI
Novel mechanism of intestinal stem cell aging$505,734
R01 · FY2022 · AG · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$437,202
R01 · FY2022 · CA
Administrative Core$206,162
U54 · FY2022 · DK · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2021 · DK · contact PI
Small molecules targeting RhoA for platelet cold storage in cancer care$635,494
R01 · FY2021 · HL · contact PI
Novel mechanism of intestinal stem cell aging$505,734
R01 · FY2021 · AG · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$446,129
R01 · FY2021 · CA
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2021 · CA
Administrative Core$206,139
U54 · FY2021 · DK · contact PI
Small molecules targeting RhoA for platelet cold storage in cancer care$635,494
R01 · FY2020 · HL · contact PI
Novel mechanism of intestinal stem cell aging$505,734
R01 · FY2020 · AG · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$446,129
R01 · FY2020 · CA
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2020 · CA
Small molecules targeting RhoA for platelet cold storage in cancer care$635,494
R01 · FY2019 · HL · contact PI
Cdc42, hematopoietic stem cell polarity, and cell fate$496,716
R01 · FY2019 · DK · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$446,129
R01 · FY2019 · CA
Leukemia stem cell polarity and differentiation therapy$429,520
R01 · FY2019 · CA
Blood stem cell aging and biomarker studies$390,000
R01 · FY2019 · HL · contact PI
Targeting Cdc42 for bone marrow transplant therapies$346,144
R01 · FY2019 · CA · contact PI
Cdc42, hematopoietic stem cell polarity, and cell fate$496,716
R01 · FY2018 · DK · contact PI
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2018 · CA
Blood stem cell aging and biomarker studies$390,000
R01 · FY2018 · HL · contact PI
Targeting Cdc42 for bone marrow transplant therapies$356,850
R01 · FY2018 · CA · contact PI
Activated protein C peptides for radio-mitigation$292,594
R43 · FY2018 · AI
Cdc42, hematopoietic stem cell polarity, and cell fate$496,716
R01 · FY2017 · DK · contact PI
Leukemia stem cell polarity and differentiation therapy$442,805
R01 · FY2017 · CA
Blood stem cell aging and biomarker studies$390,000
R01 · FY2017 · HL · contact PI
Targeting Cdc42 for bone marrow transplant therapies$356,850
R01 · FY2017 · CA · contact PI
Activated protein C peptides for radio-mitigation$298,750
R43 · FY2017 · AI
Cdc42, hematopoietic stem cell polarity, and cell fate$496,716
R01 · FY2016 · DK · contact PI
Blood stem cell aging and biomarker studies$390,000
R01 · FY2016 · HL · contact PI
Targeting Cdc42 for bone marrow transplant therapies$356,850
R01 · FY2016 · CA · contact PI
Stem cell aging and biomarker studies$390,000
R56 · FY2015 · AG · contact PI
Targeting Cdc42 for bone marrow transplant therapies$356,850
R01 · FY2015 · CA · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$333,922
R01 · FY2015 · AG · contact PI
Cincinnati Center for Excellence in Molecular Hematology$293,603
P30 · FY2015 · DK · contact PI
Cincinnati Center for Excellence in Molecular Hematology$691,861
P30 · FY2014 · DK · contact PI
A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat$366,718
R43 · FY2014 · HL
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$344,250
R01 · FY2014 · AG · contact PI
Targeting Cdc42 in leukemia stem cells$298,713
R01 · FY2014 · CA · contact PI
Rho GTPase inhibitors for refrigerated platelet storage$224,700
R43 · FY2014 · HL
Cincinnati Center for Excellence in Molecular Hematology$49,881
P30 · FY2014 · DK · contact PI
Cincinnati Center for Excellence in Molecular Hematology$683,499
P30 · FY2013 · DK · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$325,316
R01 · FY2013 · AG · contact PI
Targeting Cdc42 in leukemia stem cells$289,474
R01 · FY2013 · CA · contact PI
Rac GTPase-Specific Small Molecular Inhibitors$227,535
R01 · FY2013 · CA · contact PI
Cincinnati Center for Excellence in Molecular Hematology$47,274
P30 · FY2013 · DK · contact PI
Cincinnati Center for Excellence in Molecular Hematology$724,661
P30 · FY2012 · DK · contact PI
Pharmacological rejuvenation of aged hematopoietic stem cells.$361,403
R43 · FY2012 · AG
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$344,250
R01 · FY2012 · AG · contact PI
Targeting Cdc42 in leukemia stem cells$307,951
R01 · FY2012 · CA · contact PI
Rac GTPase-Specific Small Molecular Inhibitors$242,044
R01 · FY2012 · CA · contact PI
Training program in hematologic and oncologic diseases$160,594
T32 · FY2012 · HL · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$38,250
R01 · FY2012 · AG · contact PI
Cincinnati Center for Excellence in Molecular Hematology$23,224
P30 · FY2012 · DK · contact PI
Multi-Photon Confocal Microscope$826,609
S10 · FY2011 · RR · contact PI
Cincinnati Center for Excellence in Molecular Hematology$691,861
P30 · FY2011 · DK · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$344,250
R01 · FY2011 · AG · contact PI
Targeting Cdc42 in leukemia stem cells$307,531
R01 · FY2011 · CA · contact PI
Rac GTPases as Targets in Lymphomagenesis$276,450
R01 · FY2011 · CA · contact PI
Rac GTPase-Specific Small Molecular Inhibitors$243,433
R01 · FY2011 · CA · contact PI
Training program in hematologic and oncologic diseases$175,894
T32 · FY2011 · HL · contact PI
Cincinnati Center for Excellence in Molecular Hematology$32,800
P30 · FY2011 · DK · contact PI
Cincinnati Center for Excellence in Molecular Hematology$714,422
P30 · FY2010 · DK · contact PI
Cell Type and Stimulus-Specific Signaling Role of CDC42 in Blood$448,125
R01 · FY2010 · HL · contact PI
Targeting Cdc42 in leukemia stem cells$315,746
R01 · FY2010 · CA · contact PI
Rac GTPases as Targets in Lymphomagenesis$285,000
R01 · FY2010 · CA · contact PI
Rac GTPase-Specific Small Molecular Inhibitors$255,099
R01 · FY2010 · CA · contact PI
Training program in hematologic and oncologic diseases$171,008
T32 · FY2010 · HL · contact PI
Rac GTPases as targets in lymphomagenesis$645,498
R01 · FY2009 · CA · contact PI
Cell Type and Stimulus-Specific Signaling Role of CDC42 in Blood$364,125
R01 · FY2009 · HL · contact PI
Rac GTPases as Targets in Lymphomagenesis$285,000
R01 · FY2009 · CA · contact PI
Rac GTPase-Specific Small Molecular Inhibitors$254,901
R01 · FY2009 · CA · contact PI
Training program in hematologic and oncologic diseases$166,252
T32 · FY2009 · HL · contact PI
Cell Type and Stimulus-Specific Signaling Role of CDC42 in Blood$62,132
R01 · FY2009 · HL · contact PI
Cell Type and Stimulus-Specific Signaling Role of CDC42 in Blood$364,125
R01 · FY2008 · HL · contact PI
Rac GTPases as Targets in Lymphomagenesis$285,000
R01 · FY2008 · CA · contact PI
Dbl-like Regulators of Small GTP-binding Proteins$282,558
R01 · FY2008 · GM · contact PI
Rho GTPase-Activating Proteins in Cancer$231,698
R01 · FY2008 · CA · contact PI
Training program in hematologic and oncologic diseases$161,573
T32 · FY2008 · HL · contact PI
Cell Type and Stimulus-Specific Signaling Role of CDC42 in Blood$364,125
R01 · FY2007 · HL · contact PI
Rac GTPases as Targets in Lymphomagenesis$285,000
R01 · FY2007 · CA · contact PI
Dbl-like Regulators of Small GTP-binding Proteins$282,558
R01 · FY2007 · GM · contact PI
Interaction of Rho GTPases with regulators and effectors$245,826
R01 · FY2007 · GM · contact PI
Rho GTPase-Activating Proteins in Cancer$231,698
R01 · FY2007 · CA · contact PI
Targeting RhoA Lymphomagenesis$72,825
R03 · FY2007 · CA · contact PI
Cell Type and Stimulus-Specific Signaling Role of CDC42 in Blood$375,000
R01 · FY2006 · HL · contact PI
Dbl-like Regulators of Small GTP-binding Proteins$290,997
R01 · FY2006 · GM · contact PI
Interaction of Rho GTPases with regulators and effectors$253,167
R01 · FY2006 · GM · contact PI
Rho GTPase-Activating Proteins in Cancer$238,618
R01 · FY2006 · CA · contact PI
Targeting RhoA Lymphomagenesis$75,000
R03 · FY2006 · CA · contact PI
Dbl-like Regulators of Small GTP-binding Proteins$292,120
R01 · FY2005 · GM
Interaction of Rho GTPases with regulators and effectors$259,260
R01 · FY2005 · GM
Rho GTPase-Activating Proteins in Cancer$244,360
R01 · FY2005 · CA
Interaction of Rho GTPases with regulators and effectors$285,676
R01 · FY2004 · GM
Rho GTPase-Activating Proteins in Cancer$264,860
R01 · FY2004 · CA
Dbl-like Regulators of Small GTP-binding Proteins$251,600
R01 · FY2004 · GM
Dbl-like Regulators of Small GTP-binding Proteins$251,600
R01 · FY2003 · GM
INTERACTION OF RHO GTPASES WITH REGULATORS AND EFFECTORS$216,318
R01 · FY2003 · GM
REGULATION AND SIGNALING OF P21-ACTIVATED KINASES$37,800
R03 · FY2003 · TW
Dbl-like Regulators of Small GTP-binding Proteins$251,600
R01 · FY2002 · GM
INTERACTION OF RHO GTPASES WITH REGULATORS AND EFFECTORS$210,104
R01 · FY2002 · GM
REGULATION AND SIGNALING OF P21-ACTIVATED KINASES$37,800
R03 · FY2002 · TW
Dbl-like Regulators of Small GTP-binding Proteins$212,807
R01 · FY2001 · GM
INTERACTION OF RHO GTPASES WITH REGULATORS AND EFFECTORS$194,958
R01 · FY2001 · GM
Dbl-like Regulators of Small GTP-binding Proteins$45,813
R01 · FY2001 · GM
REGULATION AND SIGNALING OF P21-ACTIVATED KINASES$38,466
R03 · FY2001 · TW
Dbl-like Regulators of Small GTP-binding Proteins$1
R01 · FY2001 · GM
INTERACTION OF RHO GTPASES WITH REGULATORS AND EFFECTORS$194,338
R01 · FY2000 · GM
DBL-LIKE REGULATORS OF SMALL G-PROTEINS$185,115
R01 · FY2000 · GM